目的 分析吲哚菁绿荧光导航(indocyanine green fluorescence navigation，IGFN)联合腹腔镜胆囊切除术(laparoscopic cholecystectomy，LC)治疗Ⅰ型Mirizzi综合征(Mirizzi syndrome，MS)的效果。方法 选取烟台业达医院2021年2月—2022年2月收治的52例MS患者为研究对象，按照随机数字表法分为对照组和试验组，每组各26例。对照组行常规LC治疗，试验组在上述基础上联合IGFN治疗，对比2组治疗效果。结果 试验组手术时间、术中出血量及中转开腹率分别为(74。32±12。34)min、(20。45±10。54)mL和0，均低于对照组的(95。43±16。23)min、(56。76±12。33)mL和23。08％(6/26)。试验组术后第1天引流量、拔管时间、住院时间及住院费用为(25。46±5。65)mL、(1。27±0。32)d、(2。86±0。67)d和(11325。43±1236。54)元，少于对照组的(36。75±11。54)mL、(1。98±0。31)d、(3。67±1。67)d和(12954。24±1123。24)元，差异均有统计学意义(P<0。05)。试验组并发症发生率为3。85％，低于对照组的34。62％，差异有统计学意义(P<0。05)。2组患者生活质量对比显示，试验组的生理职能、躯体疼痛、精神健康、社会功能和总体健康分别为(85。43±2。12)分、(89。86±3。26)分、(85。65±2。65)分、(88。54±2。65)分和(89。56±3。67)分，高于对照组的(71。23±3。25)分、(72。35±2。67)分、(73。43±3。17)分、(74。32±3。76)分和(79。86±3。26)分，差异均有统计学意义(P<0。05)。结论 Ⅰ型MS采取IGFN联合LC治疗效果确切，能够缩短手术时间、住院时间及拔管时间，同时能够降低术中出血量、中转开腹率、术后第1天引流量及并发症发生率，提升患者生活质量。
Study on Indocyanine Green Fluorescence Navigation Combined With Laparoscopic Cholecystectomy for the Treatment of Type Ⅰ Mirizzi Syndrome
Objective To analyze the efficacy of indocyanine green fluorescence navigation (IGFN) combined with laparoscopic cholecystectomy (LC) in the treatment of type Ⅰ Mirizzi syndrome (MS).Methods A total of 52 MS patients admitted to Yantai Yeda Hospital from February 2021 to February 2022 were selected as the research subjects.All patients were randomly divided into a control group and an experimental group according to the random number table method,with 26 patients in each group.The control group received conventional LC treatment,while the experimental group received combined IGFN treatment on the basis of the above.The treatment effects of the two groups were compared.Results The surgical time,intraoperative blood loss,and conversion to open surgery rate in the experimental group were (74.32±12.34) minutes,(20.45±10.54) mL,and 0,respectively,all lower than those in the control group (95.43±16.23) minutes,(56.76±12.33) mL,and 23.08％ (6/26).The drainage volume on the first day after surgery,extubation time,hospitalization time,and hospitalization expenses of the experimental group were (25.46±5.65) mL,(1.27±0.32) d,(2.86±0.67) d,and (11325.43±1236.54) yuan,which were lower than those of the control group (36.75±11.54) mL,(1.98±0.31) d,(3.67±1.67) d,and (12954.24±123.24) yuan,and the differences were statistically significant (P<0.05).The incidence of complications in the experimental group was 3.85％,which was lower than the 34.62％ in the control group,and the differences were statistically significant (P<0.05).The comparison of quality of life between two groups of patients showed that the physiological function,physical pain,mental health,social function,and general health of the experimental group were (85.43±2.12) points,(89.86±3.26) points,(85.65±2.65) points,(88.54±2.65) points and (89.56±3.67) points,respectively,which were significantly higher than those of the control group (71.23±3.25) points,(72.35±2.67) points,(73.43±3.17) points,(74.32±3.76) points and (79.86±3.26) points,and the differences were statistically significant (P<0.05).Conclusion The combination of IGFN and LC therapy is effective in treating type Ⅰ MS,which can shorten surgical time,hospitalization time,and extubation time.At the same time,it can reduce intraoperative bleeding,conversion to open surgery rate,postoperative drainage volume on the first day,and incidence of complications,and improve the quality of life of patients.
indocyanine green fluorescence navigationlaparoscopecholecystectomytype Ⅰ Mirizzi syndromesurgical indicatorscomplicationquality of life
万方数据
维普
